1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Metrics vs Peers
3. Valuation
4. Offer Terms
5. Financial Statements
Discussion
Research report, target price, DCF and forensic scores are for subscribers. View plans
Symbol
LABT
Listed on
2026-04-23
Sector
Health Care
Subsector
Pharmaceuticals
Offer Range
—
Shares Offered
4.69M
2.37M
$112.1M
197.9%
Implied Upside vs Midpoint
Description
—
| Metric | Value | Peer median | Among peers | |
|---|---|---|---|---|
Net cash / market cap | 0.2% | 1.3% | ||
Debt / equity | 0.00 | 0.00 | ||
Current ratio | 0.13 | 0.84 | ||
9 premium metrics: DCF value / price, Growth the price needs: how common, Last 12 months vs full year and 6 more Unlock | ||||
Each filing is plotted ahead of the first trading day on the price chart.
| Filed | Form | Price range | Price | Shares offered | Deal size |
|---|---|---|---|---|---|
| 2026-01-09 | S-1 | — | — | 4,689,177 | — |
| 2026-02-05 | S-1/A | — | — | 4,689,177 | — |
| 2026-02-13 | S-1/A | — | — | 4,689,177 | — |
| 2026-03-11 | S-1/A | — | — | 4,689,177 | — |
| 2026-04-01 | S-1/A | — | — | 4,689,177 | — |
| 2026-04-06 | S-1/A | — | — | 4,689,177 | — |
| 2026-04-23 | 424B4 | — | — | 4,689,177 | — |
| 2026-04-30 | 424B3 | — | $10.00 | — | — |
Lakewood-Amedex Biotherapeutics Inc. income statement and balance sheet, FY Dec 2025 to FY Dec 2025, as reported in SEC filings.
| Metric | FY Dec 2025 |
|---|---|
| Total assets | $482K |
| Total liabilities | $2.4M |
| Total equity | ($2.0M) |
| Cash & equivalents | $236K |